top of page

Hemlibra Fatalities Now at 23!

Updated: Jul 22, 2020

Well, like clockwork, Genentech has released the quarterly fatalities report for Hemlibra.(Emicizumab)

A few weeks ago, we published a post about the New England Journal of Medicine publishing a letter to the Editor from Louis M. Aledort, M.D.

Dr. Aledort stated that " It is understandable that both patients with hemophilia A and their physicians are enthusiastic about the potential advantages of subcutaneous administration of emicizumab. However, I am concerned that we may be seeing the beginning of a serious public health issue. This population of patients has already been exposed to risks associated with therapy, and we should embrace this very important biologic agent with caution. "

We will be following up next quarter on the next fatalities report. The number will mostly likely be over 30. Anyone wanna start placing bets?


Recent Posts

See All
bottom of page